Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7062
Title: | 18-Fluoride fluorodeoxyglucose positron emission tomography is impactful in newly diagnosed pancreatic adenocarcinoma |
Authors: | Power, J.;Larcos, George |
WSLHD Author: | Larcos, George |
Issue Date: | 2023 |
Citation: | ANZ Journal of Surgery 93(1-2):145-150, 2023 |
Abstract: | BACKGROUND: Adenocarcinoma of the pancreas has a dismal prognosis. Surgical resection increases survival but is reliant on accurate detection and staging of disease. In overseas studies, 18 F-FDG positron emission tomography (PET) has been shown to have high diagnostic accuracy and staging utility, but local data remain sparse, in part because the technique has hitherto been unfunded via the Medicare benefits schedule. Although Commonwealth funding for rare tumours (including of the pancreas) has been recently approved to commence in late 2022, the proposed item descriptor wording implies that PET should lead to a significant change in management. Accordingly, the aims of this study are to characterize PET findings in newly diagnosed pancreatic adenocarcinoma using standard parameters, such as the SUVmax , and assess the proportion of cases in which PET altered initial management planning. METHODS: We analysed the PET findings of these cancers (presence and degree of metabolic activity in the primary lesion, as well as within malignant nodal and metastatic lesions) and compared the pre- and post-PET management plans of the referring specialists. RESULTS: Of 51 patients we found that (a) increasing SUVmax of the primary lesion correlated with an increase in disease stage (r-value = 0.335; P-value = 0.016), and (b) PET contributed to a significant change in management in 35% of patients. CONCLUSION: In newly diagnosed pancreatic adenocarcinoma, parameters in PET correlate with disease stage and the overall findings contribute to a significant management change in about 35% of patients. Copyright �� 2022 The Authors. ANZ Journal of Surgery published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons. |
URI: | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7062 |
DOI: | https://dx.doi.org/10.1111/ans.18236 |
Journal: | ANZ Journal of Surgery |
Type: | Journal Article |
Department: | Nuclear Medicine and Ultrasound |
Facility: | Westmead |
Keywords: | United States Pancreatic Neoplasms Radiopharmaceuticals Adenocarcinoma Medicare Positron-Emission Tomography Neoplasm Staging |
Appears in Collections: | Westmead Hospital 2019 - 2024 |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.